Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
This article was originally published in The Pink Sheet Daily
Executive Summary
Rather than financial considerations, Ono Pharmaceutical will receive co-development and co-commercialization rights to rheumatoid arthritis drug Orencia in Japan.
You may also be interested in...
BMS’ Andreotti Talks BD Beyond 2015
Oncology, virology and cardiovascular remain top therapeutic priorities in mid-term, but longer term focus at BMS is shifting to oncology, CNS and cardiovascular and metabolic diseases, CEO Lamberto Andreotti tells analysts at Sanford F. Bernstein conference.
Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure
Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.
Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure
Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.